XML 53 R41.htm IDEA: XBRL DOCUMENT v3.6.0.2
Agreements - Amgen (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 204 Months Ended
Feb. 29, 2016
item
Dec. 31, 2015
item
Sep. 30, 2015
USD ($)
Oct. 31, 2013
USD ($)
May 31, 2013
USD ($)
item
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Dec. 31, 2016
USD ($)
item
Dec. 31, 2015
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Dec. 31, 2000
USD ($)
item
Dec. 31, 2016
USD ($)
Collaborative Agreements disclosures                                            
Amount of arrangement consideration included in license and milestone fees           $ 5,076,000 $ 76,000 $ 76,000 $ 10,077,000 $ 10,692,000 $ 6,070,000 $ 5,086,000 $ 5,078,000 $ 41,417,000 $ 6,234,000 $ 5,152,000 $ 16,762,000 $ 26,915,000 $ 57,815,000 $ 39,455,000    
Costs related to the research and development services           33,657,000 $ 32,909,000 $ 38,652,000 $ 36,094,000 $ 38,199,000 $ 35,132,000 $ 30,437,000 $ 25,666,000 $ 27,647,000 $ 28,018,000 $ 66,566,000 $ 73,331,000 148,077,000 111,768,000 106,958,000    
Amgen                                            
Collaborative Agreements disclosures                                            
Number of single-target licenses | item   4     1                     2         3  
Fee received per license       $ 500,000 $ 500,000                               $ 1,000,000  
Number of licenses terminated | item 2 2                                        
Potential milestone payments       $ 34,000,000                                    
Estimated term of development and commercialization license       25 years                                    
Discount rate (as a percent)       13.00%                                    
Remaining arrangement consideration to be recognized as license revenue       $ 430,000                                    
Amount of arrangement consideration included in license and milestone fees                                       2,200,000   $ 3,000,000
Estimated utilization period after commercialization       10 years                                    
Costs related to the research and development services                               $ 0   15,000 62,000 179,000    
Costs related to clinical materials sold                               0   $ 0 $ 0 $ 664,000    
Amgen | Development milestones                                            
Collaborative Agreements disclosures                                            
Potential milestone payments       $ 9,000,000                                    
Amgen | IND application filed                                            
Collaborative Agreements disclosures                                            
Potential milestone payments           1,000,000                   1,000,000           1,000,000
Amount of arrangement consideration included in license and milestone fees     $ 1,000,000                                      
Amgen | Phase II clinical trial                                            
Collaborative Agreements disclosures                                            
Potential milestone payments           $ 3,000,000                   $ 3,000,000           $ 3,000,000
Amgen | Regulatory milestones                                            
Collaborative Agreements disclosures                                            
Potential milestone payments       20,000,000                                    
Amgen | Sales milestones                                            
Collaborative Agreements disclosures                                            
Potential milestone payments       $ 5,000,000